Abiraterone-d4

• UNSPSC Description:

  Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.

• Target Antigen:

  Cytochrome P450

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Purity:

  98.0

• Solubility:

  Ethanol : 5 mg/mL (ultrasonic;warming)

• Smiles:

  C[C@@]12C(C3=C([2H])N=C([2H])C([2H])=C3[2H])=CC[C@]1([C@@]4(CC=C5[C@@](C)([C@]4(CC2)[H])CC[C@@H](C5)O)[H])[H]

• Molecular Weight:

  353.53

• References & Citations:

  [1]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71.;Richards J, et al. Interactions of|[2]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  2122245-62-7